Company / Accounts Receivable
INOVIO PHARMACEUTICALS, INC. Accounts Receivable History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$1.2M
FY2024
5-year range
$1.2M / $5.5M
FY2020-FY2024
Trend
-
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Accounts Receivable has declined for 3 consecutive years, from $19M in FY2020 to $1M in FY2024.
Based on SEC 10-K filings.
$1M in FY2024 with a 5-year CAGR of +11.4%.
Declined from $5M to $1M over the past 3 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -39.7%
- 5-Year CAGR
- +11.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +11.4%, indicating consistent growth.
- Peak accounts receivable was recorded in FY2020.
- Lowest accounts receivable in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $1.2M | - |
| FY2023 | - | - |
| FY2022 | $1.7M | -68.9% |
| FY2021 | $5.5M | -70.5% |
| FY2020 | $18.6M | +2551.1% |
| FY2019 | $700.1K | -78.9% |
| FY2018 | $3.3M | -44.8% |
| FY2017 | $6.0M | -62.1% |
| FY2016 | $15.8M | +115.8% |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026